Origami Therapeutics is a preclinical-stage company developing novel protein degrader therapeutics with a proprietary drug discovery platform which holds the promise for disease-modification in neurodegenerative diseases such as Huntington’s Disease. We are pioneering the next-generation of small molecules targeting disease-causing proteins. At Origami Therapeutics, we’re leading the creation of an entirely new way to treat disease through therapies that target and degrade disease-related proteins. We are a preclinical-stage biopharmaceutical company focused on developing new therapeutics for neurodegenerative diseases, beginning with Huntington’s Disease. Our proprietary protein degraders work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins. We have built upon groundbreaking research of our founder Beth Hoffman, a veteran drug discovery scientist who discovered transformational therapeutics for cystic fibrosis. Origami is developing a broad technology platform focused on high-value targets, with the potential to deliver more potent therapies and to address the >80% of proteins that evade inhibition and have been “undruggable” by traditional approaches. Our lead programs are focused on neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD) and Huntington’s disease (HD). Our hope is to unlock the full potential of ORIGAMI protein degradation by developing our own robust pipeline and by partnering with the world’s leading drug development companies.